Patents by Inventor Richard Blumberg
Richard Blumberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939566Abstract: A system and method for growing and maintaining biological material including producing a protein associated with the tissue, selecting cells associated with the tissue, expanding the cells, creating at least one tissue bio-ink including the expanded cells, printing the at least one tissue bio-ink in at least one tissue growth medium mixture, growing the tissue from the printed at least one tissue bio-ink, and maintaining viability of the tissue.Type: GrantFiled: September 2, 2021Date of Patent: March 26, 2024Assignee: DEKA Products Limited PartnershipInventors: Christopher C. Langenfeld, David D. B. Cannan, Dirk A. van der Merwe, Dean Kamen, Jason A. Demers, Frederick Morgan, Timothy D. Moreau, Brian D. Tracey, Matthew Ware, Richard J. Lanigan, Michael A. Baker, David Blumberg, Jr., Richard E. Gautney, Derek G. Kane, Dane Fawkes, Thomas J. Bollenbach, Michael C. Tilley, Stuart A. Jacobson, John F. Mannisto
-
Patent number: 8886979Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: GrantFiled: June 10, 2013Date of Patent: November 11, 2014Assignee: Intel CorporationInventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Publication number: 20130275787Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: ApplicationFiled: June 10, 2013Publication date: October 17, 2013Inventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Patent number: 8479029Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: GrantFiled: June 24, 2011Date of Patent: July 2, 2013Assignee: Intel CorporationInventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Patent number: 8173123Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.Type: GrantFiled: February 19, 2010Date of Patent: May 8, 2012Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Brigham & Women's HospitalInventors: Warren Strober, Ivan J. Fuss, Frank Heller, Richard Blumberg
-
Publication number: 20110252255Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: ApplicationFiled: June 24, 2011Publication date: October 13, 2011Inventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Publication number: 20110189181Abstract: The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described.Type: ApplicationFiled: August 2, 2010Publication date: August 4, 2011Inventors: Nalan Utku, Steven Richard Blumberg
-
Patent number: 7992017Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: GrantFiled: September 11, 2007Date of Patent: August 2, 2011Assignee: Intel CorporationInventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Publication number: 20090070607Abstract: Methods and apparatuses for reducing step loads of processors are disclosed. Method embodiments comprise examining a number of instructions to be processed by a processor to determine the types of instructions that it has, calculating power consumption by in an execution period based on the types of instructions, and limiting the execution to a subset of instructions of the number to control the quantity of power for the execution period. Some embodiments may also create artificial activity to provide a minimum power floor for the processor. Apparatus embodiments comprise instruction type determination logic to determine types of instructions in an incoming instruction stream, a power calculator to calculate power consumption associated with processing a number of instructions in an execution period, and instruction throttling logic to control the power consumption by limiting the number of instructions to be processed in the execution period.Type: ApplicationFiled: September 11, 2007Publication date: March 12, 2009Inventors: Kevin Safford, Rohit Bhatia, Chris Bostak, Richard Blumberg, Blaine Stackhouse, Steve Undy
-
Publication number: 20080026980Abstract: The use of an agent that selectively modulates cross-linking of biliary glycoprotein polypeptides for the preparation of a pharmaceutical composition for preventing or treatment of a mammal subject afflicted with an inflammatory disease is provided. In particular, a method for preventing or treatment of a mammal subject afflicted with rheumatoid arthritis or multiple sclerosis, comprising the step of administering to a mammal in need thereof a therapeutic effective amount of a fusion protein of a fragment of biliary glycoprotein and a fragment of an immunoglobulin is described.Type: ApplicationFiled: December 17, 2004Publication date: January 31, 2008Inventors: Nalan Utku, Steven Richard Blumberg
-
Publication number: 20070020192Abstract: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.Type: ApplicationFiled: February 23, 2006Publication date: January 25, 2007Applicants: The Brigham and Women's Hospital, Inc., Brandeis UniversityInventors: Richard Blumberg, Neil Simister, Wayne Lencer
-
Publication number: 20060293288Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of EPA and DHA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of EPA or DHA (resolvins of the E series and D series) that diminish, prevent, or eliminate gastrointestinal conditions, for example, such as colitis. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.Type: ApplicationFiled: January 5, 2006Publication date: December 28, 2006Inventors: Charles Serhan, Makoto Arita, Masaru Yoshida, Richard Blumberg
-
Publication number: 20060140907Abstract: The present invention relates to methods and products for the transepithelial systemic delivery of therapeutics. In particular, the invention relates to methods and compositions for the systemic delivery of therapeutics by administering an aerosol containing antibodies or conjugates of a therapeutic agent with an FcRn binding partner to epithelium of central airways of the lung. The methods and products are adaptable to a wide range of therapeutic agents, including proteins and polypeptides, nucleic acids, drugs, and others. The methods and products have the advantage of not requiring administration to the deep lung in order to effect systemic delivery.Type: ApplicationFiled: January 20, 2006Publication date: June 29, 2006Inventors: Richard Blumberg, Wayne Lencer, Neil Simister, Alan Bitonti
-
Publication number: 20060024306Abstract: Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.Type: ApplicationFiled: June 14, 2002Publication date: February 2, 2006Inventors: Warren Strober, Ivan Fuss, Frank Heller, Richard Blumberg
-
Publication number: 20050234073Abstract: The invention provides a method of inhibiting inflammation in a mammal, by administering to the mammal composition containing a compound which inhibits the expression or activity of a microsomal triglyceride transfer protein.Type: ApplicationFiled: February 9, 2005Publication date: October 20, 2005Inventor: Richard Blumberg
-
Publication number: 20050169922Abstract: The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided.Type: ApplicationFiled: February 2, 2005Publication date: August 4, 2005Inventor: Richard Blumberg
-
Publication number: 20050090426Abstract: The invention provides a method of inhibiting inflammation in a mammal, by administering to the mammal composition containing a compound which inhibits the expression or activity of a microsomal triglyceride transfer protein.Type: ApplicationFiled: March 24, 2004Publication date: April 28, 2005Inventor: Richard Blumberg
-
Patent number: D367513Type: GrantFiled: January 24, 1994Date of Patent: February 27, 1996Inventor: Richard A. Blumberg